This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.

Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension.

Biocon's subsidiary has received approval from the US Food and Drug Administration (US FDA) for its ANDA Norepinephrine ...

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...

The approval covers the norepinephrine bitartrate injection 4 mg/4 mL (1 mg/mL) single-dose vial, which can now be ...

Norepinephrine bitartrate injection is a critical medication used to raise blood pressure in adult patients suffering from ...

Biocon Pharma Limited receives FDA approval for Norepinephrine Bitartrate Injection USP, expanding its complex drug portfolio ...

Biocon added 1.34% to Rs 348.55 after the company's wholly owned subsidiary Biocon Pharma announced the receipt of U.S Food and Drug Administration (US FDA) approval for its ANDA Norepinephrine ...

College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for ...